Pfizer’s full-year revenues grow 23%, top $100B

Pfizer reported full-year revenues of $100.3 billion, marking 23% year-over-year growth, the company announced Tuesday morning.

Pfizer benefited from the continued strong performance of its COVID-19 treatments Paxlovid and Comirnaty. Looking ahead to next year, the company projects revenues of $13.5 billion for its COVID-19 vaccine and $8 billion for Paxlovid.